The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
Weight-loss drugs swell revenues at Eli Lilly
Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Endocrinology Advisor3d
Gastrointestinal Adverse Events Mediate Some Tirzepatide-Associated Weight Loss
Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.
Whoopi Goldberg addresses 'phony weight loss ad' depicting her on Instagram
"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...
Is Compounded Semaglutide Effective for Weight Loss?
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Impacts11d
What is Mounjaro Weight Loss? How does it Works?
Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...
Psychology Today4d
New Weight Loss Medications May Help Treat Addiction
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
New Atlas16h
Ozempic is suspected in more cases of sudden vision loss
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Pros and cons of weight-loss jabs
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...